| Title | Published | Price |
|---|---|---|
Bangladesh Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Out of the 16 key markets surveyed in BMI’s Pharmaceuticals & Healthcare Business Environment Ratings, Bangladesh moves up two places to occupy 14th position in the table. This improvement sees it now placing above Pakistan and Cambodia, th... |
June 2010 | $ 530 |
Chile Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Report SummaryIn BMI’s Q310 Business Environment Ratings for the 17 markets of the Americas, Chile receives a composite pharmaceutical rating of 37.6, falling to 11th place in the Americas matrix of countries. We note... |
July 2010 | $ 530 |
India Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Report SummaryIt is BMI's view that India's attractiveness to drugmakers is improving dramatically. According to primary market research firm AIOCD Pharmasofttech AWACS, sales of pharmaceuticals expanded by 23.0% in... |
July 2010 | $ 530 |
Iraq Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Report SummaryThe growth of Iraq’s pharmaceutical market in the long-term is inextricably linked to an oil-driven economic expansion, which in turn depends on the government’s ability to represent and appease th... |
July 2010 | $ 530 |
Morocco Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Report SummeryBMI’s Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underline some of our key views about how the sector is performing in emerging markets. In particular, we hig... |
July 2010 | $ 530 |
Lithuania Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Report SummeryOur new Q310 Business Environment Ratings (BER) matrix for Emerging Europe places Lithuania in 15th position of the 20 markets surveyed. Lithuania’s pharmaceutical market score is the second-lowest in th... |
July 2010 | $ 530 |
Oman Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International BMI's Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical marketunderlines some of our key views for how the sector is performing in emerging markets. In particularwe highlight Saudi Arabia, Egypt and ... |
July 2010 | $ 530 |
France Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International France scores well in our Q310 Pharmaceuticals and Healthcare Business Environment Ratings – it isranked 10th globally (out of the 82 markets in BMI’s coverage universe) and fourth in our WesternEuropean matrix of nine countries. ... |
July 2010 | $ 530 |
Spain Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International In BMI’s Business Environment Ratings for Q310, Spain continued to fall down the matrix. It is now ratedeighth out of the 10 countries surveyed, having already dropped one place to fifth in the previous quarter.While Spain offers ... |
July 2010 | $ 530 |
Peru Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BER) for Q310, we havesignificantly expanded the number of countries surveyed in the Americas region. Peru now places eighthof the 17 markets, let down by its sma... |
July 2010 | $ 530 |
Russia Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International In line with Russia’s economic recovery this year, BMI expects the pharmaceutical sector to post 22.4% USdollar growth in 2010 – a figure enhanced by the appreciation of the rouble in relation to the US dollar. TheRussian market i... |
July 2010 | $ 530 |
Vietnam Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International In our Asia Pacific Business Environment Ratings (BER) matrix for Q310, Vietnam remains ranked 13th,out of 16 key regional markets, which now include Cambodia. Despite a marginally improved score,Vietnam is still regarded as one o... |
July 2010 | $ 530 |
Slovakia Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International In the BMI emerging Europe pharmaceutical Business Environment Ratings for Q310, Slovakia scored avirtually unchanged 56.7. However, this score now puts Slovakia in seventh position out of the 20regional markets surveyed, down two... |
July 2010 | $ 530 |
Ghana Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International In the BMI’s Business Environment Ratings (BER) for the 19 markets in the Middle East and Africa(MEA) region, Ghana receives a composite pharmaceutical rating of 39.1, ranking the country 15th, thusabove Nigeria, a market with sim... |
July 2010 | $ 530 |
Malaysia Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Leading Malayisan drugmaker Pharmaniaga expects the outlook for the Malaysian pharmaceutical industry toimprove in 2010. This view is in accordance with BMI's Pharmaceutical Expenditure Forecast Model, which showsthat medicine sal... |
July 2010 | $ 530 |
United States Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International The outcomes of the US healthcare reforms have generally been viewed negatively by Big Pharma.Despite the potentially profit-limiting changes of reform, the US remains the highest potentialpharmaceutical market globally. Reinforci... |
July 2010 | $ 530 |
Greece Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Pharmaceutical companies in Greece face unprecedented challenges. The dire fiscal situation in thecountry is translating into clear operating difficulties for the industry, both in Greece and potentiallyelsewhere. While Greece mai... |
June 2010 | $ 530 |
Bulgaria Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International BMI considers Bulgaria to be among the less attractive pharmaceutical markets in Emerging Europe, a view largely enforced by poor market dynamics and prolonged economic difficulties. In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings for |
June 2010 | $ 530 |
Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International BMI retains its robust five-year growth forecast for the Kazakhstan pharmaceutical market, with the US dollar value of the market rebounding on the back of a resurgent local currency in 2010. Our forecast sees a strong economy – driven by increasing oil |
June 2010 | $ 530 |
Belgium Pharmaceuticals and Healthcare Report Q3 2010By Business Monitor International Having received a somewhat lower compound score in Q310, Belgium is now placed joint fifth in the Western Europe Pharmaceuticals & Healthcare Business Environment Ratings (BER) matrix, on a par with the UK and below Germany, Switzerland and new inclusio |
June 2010 | $ 530 |
Posted by
a
on
categories: